LncRNA GAS5 Regulates Gemcitabine Resistance in Pancreatic Carcinoma by Targeting miRNA-21
K Huang, G Yang - Annals of Clinical & Laboratory Science, 2023 - Assoc Clin Scientists
Objective Gemcitabine is the first-line drug for chemotherapy of pancreatic cancer. However,
owing to the inherent and acquired resistance, gemcitabine does not change obviously the …
owing to the inherent and acquired resistance, gemcitabine does not change obviously the …
LncRNA GAS5 Regulates Gemcitabine Resistance in Pancreatic Carcinoma by Targeting miRNA-21.
K Huang, G Yang - Annals of Clinical and Laboratory Science, 2023 - europepmc.org
Objective Gemcitabine is the first-line drug for chemotherapy of pancreatic cancer. However,
owing to the inherent and acquired resistance, gemcitabine does not change obviously the …
owing to the inherent and acquired resistance, gemcitabine does not change obviously the …
LncRNA GAS5 Regulates Gemcitabine Resistance in Pancreatic Carcinoma by Targeting miRNA-21
K Huang, G Yang - Annals of clinical and laboratory …, 2023 - pubmed.ncbi.nlm.nih.gov
Objective Gemcitabine is the first-line drug for chemotherapy of pancreatic cancer. However,
owing to the inherent and acquired resistance, gemcitabine does not change obviously the …
owing to the inherent and acquired resistance, gemcitabine does not change obviously the …